生命科学资讯
生物技术与制药领域的最新动态
Lilly pays CSL $100M upfront for IL-6 antibody that flunked a phase 3 organ transplant study
Korsana crosses into crowded Alzheimer's field with $175M and anti-amyloid antibody
免疫学CRO RoukenBio与AVS Bio签署协议,提升抗体开发可预测性。
Immunology CRO RoukenBio pens pact with AVS Bio for more predictable antibody development
细胞疗法公司拟募资9200万美元,有望终结东京生物科技IPO荒。
Cell therapy company hopes to end Tokyo biotech IPO drought with $92M offering
勃林格殷格翰在审查囊性纤维化数据后停止吸入基因疗法研发。
Boehringer axes inhaled gene therapy after viewing cystic fibrosis data
赛诺菲与梯瓦合作研发的IBD药物长期数据展现"关键机遇"。
Sanofi points to 'key opportunity' for Teva-partnered IBD in long-term data
指南针引领迷幻疗法在抑郁症治疗中取得第二项关键性胜利,推动审批进程加速。
Compass guides psychedelic therapy to 2nd pivotal depression win, triggering approval push
Cyrano在中期嗅觉丧失试验中获胜后,关键性试验即将展开。
Cyrano noses toward pivotal trial after midphase smell loss win
Novocure获FDA批准,电场疗法瞄准胰腺癌治疗。
Novocure gets FDA nod for tumor-treating electric fields targeting pancreatic cancer
吉利德以15亿美元与中国亘喜生物达成最新合成致死疗法协议。
Gilead’s latest synthetic lethal therapy comes via $1.5B deal with China’s Genhouse
2026年生物制药融资展望:PitchBook预测将迎来“持续而审慎”的复苏。
Biopharma funding to experience 'continued, albeit disciplined' recovery in 2026: PitchBook
'对患者来说,这确实是艰难时刻':Biohaven首席执行官称FDA繁文缛节阻碍罕见病治疗药物获取
'It's really a dire time for patients': Biohaven CEO says FDA red tape is blocking access to rare disease treatments
尽管有局长优惠券,FDA仍拒绝批准Disc公司的罕见病药物。
FDA rejects Disc's rare disease drug despite commissioner's voucher
随着FDA对Moderna的决定,疫苗制造商面临日益不确定的监管环境
With the FDA's Moderna decision, vaccine makers face increasingly uncertain regulatory environment
FDA批准Encora Therapeutics可穿戴腕部设备用于治疗特发性震颤。
FDA clears Encora Therapeutics’ wearable wrist device for essential tremor
2025年临床试验最大失败案例有哪些?
What were the biggest clinical trial flops of 2025?
研发主管离职后,Immunocore首席执行官对扩大癌症产品组合既怀雄心又持谨慎态度。
After R&D head exits, Immunocore CEO pairs ambition with caution for growing cancer portfolio
《蛇梯棋》——赛诺菲CEO惊人换帅
Chutes & Ladders—Sanofi's stunning CEO switch
Integra LifeSciences削减职位,新泽西州普林斯顿站点65名员工受影响。
Integra LifeSciences cuts roles as 65 staffers impacted from Princeton, N.J., site